Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Payables: 2013-2024

Historic Payables for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Dec 2024 value amounting to $157.1 million.

  • Amphastar Pharmaceuticals' Payables rose 24.52% to $190.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $690.4 million, marking a year-over-year increase of 39.60%. This contributed to the annual value of $157.1 million for FY2024, which is 68.22% up from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its Payables stood at $157.1 million for FY2024, which was up 68.22% from $93.4 million recorded in FY2023.
  • Amphastar Pharmaceuticals' Payables' 5-year high stood at $157.1 million during FY2024, with a 5-year trough of $84.2 million in FY2022.
  • For the 3-year period, Amphastar Pharmaceuticals' Payables averaged around $111.6 million, with its median value being $93.4 million (2023).
  • Its Payables has fluctuated over the past 5 years, first fell by 6.24% in 2021, then soared by 68.22% in 2024.
  • Yearly analysis of 5 years shows Amphastar Pharmaceuticals' Payables stood at $95.5 million in 2020, then fell by 6.24% to $89.5 million in 2021, then declined by 5.92% to $84.2 million in 2022, then grew by 10.83% to $93.4 million in 2023, then skyrocketed by 68.22% to $157.1 million in 2024.